Search

Background: The benefit of percutaneous mitral valve repair (PMVR) in patients with secondary MR is still debated. We aimed to compare the outcome of PMVR with optimal medical therapy (OMT) versus OMT alone in patients with secondary mitral regurgitation (MR) and to assess the role of potential effect modifiers., Methods: We performed a systematic review and meta-analysis of 2 randomized clinical trials (RCT) and 7 non-randomized observational studies (nROS). Hazard ratios (HR) and 95% confidence intervals (CI) were pooled through inverse variance random-effects model to compute the summary effect size for all-cause death, cardiovascular death and cardiac-related hospitalization. Subgroup and meta-regression analysis were also performed., Results: An overall population of 3118 individuals (67% men; mean age, 73 years) was included: 1775 PMVR+OMT and 1343 OMT patients, with mean follow-up of 24 ± 15 months. PMVR+OMT was associated with a lower risk of all-cause death (HR: 0.77; 95% CI: 0.68-0.87), cardiovascular death (HR: 0.55; 95% CI: 0.34-0.89) and cardiac-related hospitalization (HR:0.77; 95% CI: 0.64-0.92). Meta-regression analysis showed that larger left ventricular end-diastolic volume index (LVEDVI) portends higher risk of all-cause death, cardiovascular death and cardiac-related hospitalization after PMVR (p < 0.001 for all)., Conclusions: This study-level meta-analysis shows that PMVR+OMT is associated with reduced all-cause death, cardiovascular death and cardiac-related hospitalization when compared with OMT alone in secondary MR. LVEDVI is a predictive marker of efficacy, as patients with smaller LVEDVI have been shown to derive the largest benefit from PMVR., Competing Interests: Declaration of competing interest Marco Zimarino: Name of Entity: None. Fabrizio Ricci: Name of Entity: None. Davide Capodanno: Name of Entity: Abbott Vascular, Financial Relationship: Consulting Fee, Amount: Modest. Carlo De Innocentiis: Name of Entity: None. Martin J. Swaans: Name of Entity: Abbott Vascular, Financial Relationship: Consulting Fee, Amount: Modest. Name of Entity: Boston Scientific, Financial Relationship: Speaker Fee, Amount: Modest. Name of Entity: Philips Healthcare, Financial Relationship: Consulting Fee, Amount: Modest. Carlo Lombardi: Name of Entity: None. Jorn Brouwer: Name of Entity: None. Sabina Gallina: Name of Entity: None. Carmelo Grasso: Name of Entity: Abbott Vascular, Financial Relationship: Speaker Fee, Amount: Modest. Raffaele De Caterina: Name of Entity: Bayer, Financial Relationship: Grants, advisory board fees and support from congress participation, Amount: Modest. Name of Entity: Boehringer Ingelheim, Financial Relationship: Grants, advisory board fees and support from congress participation, Amount: Modest. Name of Entity: BMS/Pfizer, Financial Relationship: Grants, advisory board fees and support from congress participation, Amount: Modest. Name of Entity: Daiichi/ Sankyo, Financial Relationship: Grants, advisory board fees and support from congress participation, Amount: Modest. Name of Entity: Astra-Zeneca, Financial Relationship: Grants, advisory board fees and support from congress participation, Amount: Modest. Name of Entity: Roche, Financial Relationship: Grants, advisory board fees and support from congress participation, Amount: Modest. Name of Entity: Portola, Financial Relationship: Grants, advisory board fees and support from congress participation, Amount: Modest. Name of Entity: Novartis, Financial Relationship: Grants, advisory board fees and support from congress participation, Amount: Modest. Corrado Tamburino: Name of Entity: Medtronic, Financial Relationship: Consulting and Speaker Fees, Amount: Modest. Name of Entity: St. Jude, Financial Relationship: Consulting and Speaker Fees, Amount: Modest. Name of Entity: Daiichi/Sankyo, Financial Relationship: Consulting and Speaker Fees, Amount: Modest. Name of Entity: Stentys, Financial Relationship: Consulting and Speaker Fees, Amount: Modest., (Copyright © 2019 Elsevier Inc. All rights reserved.)

The burden of pregnancy-related heart disease has dramatically increased over the last decades due to the increasing age at first pregnancy and higher prevalence of cardiovascular risk factors such as diabetes, hypertension, and obesity. Pregnancy is associated with physiological changes in the cardiovascular system, including hemodynamic, metabolic, and hormonal adaptations to meet the increased metabolic demands of the mother and fetus. It has been postulated that pregnancy may act as a cardiovascular stress test to identify women at high risk for heart disease, where the inability to adequately adapt to the physiologic stress of pregnancy may reveal the presence of genetic susceptibility to cardiovascular disease or accelerate the phenotypic expression of both inherited and acquired heart diseases, such as peripartum cardiomyopathy (PPCM). PPCM is a rare and incompletely understood clinical condition. Despite recent advances in the understanding of its pathogenesis, PPCM is not attributable to a well-defined pathological mechanism, and therefore, its diagnosis still relies on the exclusion of overlapping dilated phenotypes. Cardiac imaging plays a key role in any peripartum woman with signs and symptoms of heart failure in establishing the diagnosis, ruling out life-threatening complications, guiding therapy and conveying prognostic information. Echocardiography represents the first-line imaging technique, given its robust diagnostic yield and its favorable cost-effectiveness. Cardiovascular magnetic resonance is a biologically safe high-throughput modality that allows accurate morpho-functional assessment of the cardiovascular system in addition to the unique asset of myocardial tissue characterization as a pivotal piece of information in the pathophysiological puzzle of PPCM. In this review, we will highlight current evidence on the role of multimodality imaging in the differential diagnosis, prognostic assessment, and understanding of the pathophysiological basis of PPCM., (Copyright © 2020 Ricci, De Innocentiis, Verrengia, Ceriello, Mantini, Pietrangelo, Irsuti, Gabriele, D'Alleva, Khanji, Aung, Renda, Cameli, Petersen, Di Cesare and Gallina.)

Distinguishing between adaptive and maladaptive cardiovascular response to exercise is crucial to prevent the unnecessary termination of an athlete's career and to minimize the risk of sudden death. This is a challenging task essentially due to the substantial phenotypic overlap between electrical and structural changes seen in the physiological athletic heart remodeling and pathological changes seen in inherited or acquired cardiomyopathies. Stress testing is an ideal tool to discriminate normal from abnormal cardiovascular response by unmasking subtle pathologic responses otherwise undetectable at rest. Treadmill or bicycle electrocardiography, transthoracic echocardiography, and cardiopulmonary exercise testing are common clinical investigations used in sports cardiology, specifically among participants presenting with resting electrocardiographic abnormalities, frequent premature ventricular beats, or non-sustained ventricular arrhythmias. In this setting, as well as in cases of left ventricular hypertrophy or asymptomatic left ventricular dysfunction, stress imaging and myocardial tissue characterization by cardiovascular magnetic resonance show promise. In this review, we aimed to reappraise current diagnostic schemes, screening strategies and novel approaches that may be used to distinguish adaptive remodeling patterns to physical exercise from early phenotypes of inherited or acquired pathological conditions commanding prompt intervention.

Objectives: Microalbuminuria (MAU) is associated with an enhanced risk of cardiovascular events. The prevalence of MAU and its prognostic impact has an important role in the stratification of cardiovascular risk in patients with essential hypertension. This is an observational, prospective study performed by 13 general practitioners aiming at assessing the prevalence and prognostic relevance of MAU in essential hypertension., Methods: Patients with essential hypertension and with recent determination of MAU were enrolled into the study by general practitioners, and were followed up for 3 years. Primary end point was the occurrence of major cardiovascular events during the follow-up., Results: Out of 1024 unselected patients, consecutively enrolled from January 2009 to March 2010, 804 completed the 3-year follow-up. Patients were categorized into two groups according to the absence (n = 523, 65%) or presence (n = 281, 35%) of MAU. During the follow-up, 41 cardiovascular events (1.69 events/100 patient-years) were reported. The presence of MAU was not associated with increased risk of cardiovascular events (adjusted hazard ratio = 1.32; 95% confidence interval 0.290-4.340, P = 0.097). When the analysis was restricted to the patients with previous cardiovascular event, MAU (adjusted hazard ratio = 2.18; 95% confidence interval 0.42-2.43, P = 0.031), together with age, metabolic syndrome, diabetes, and smoking, independently predicted the occurrence of cardiovascular events., Conclusion: Presence of MAU in patients with essential hypertension is not associated with increased risks of cardiovascular events. At the variance, in patients with previous cardiovascular events, MAU was found to predict recurrent events. Thus, the assessment of MAU could be considered a useful tool in secondary prevention.